![Dhavalkumar Patel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Förmögenhet: 347 290 $ per 2026-06-30
Dhavalkumar Patel was the founder of Priothera Ltd., founded in 2020, holding the title of Director.
Current jobs include Chairman at Mimetas BV since 2022, Director at RA Pharmaceuticals, Inc. since 2020, Director at Anokion SA, Director at Kanyos Bio, Inc., Director at Quell Therapeutics Ltd., and Chief Scientific Officer & Executive VP at Sana Biotechnology, Inc. since 2024.
Former jobs include Independent Director at Inflazome Ltd. from 2017 to 2020, Global Head-Autoimmunity at Novartis International AG from 2006 to 2017, Chief Scientific Officer & Executive VP at UCB SA from 2017 to 2024, Professor at The University of North Carolina at Chapel Hill from 2003 to 2006, Head-Allergy & Immunology at Duke University School of Medicine from 2002 to 2003, Head-Research at Novartis Institutes for Biomedical Research, Inc., and Professor at Duke University Medical Center from 1994 to 2003.
Education includes undergraduate, graduate, and doctorate degrees from Duke University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SANA BIOTECHNOLOGY, INC. 0,04 % | 2026-03-24 | 99 510 ( 0,04 % ) | 347 290 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2024-08-26 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Direktör/Styrelseledamot | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Direktör/Styrelseledamot | - |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Direktör/Styrelseledamot | - |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Ordförande | 2022-09-01 |
| Företag | Position | Slut |
|---|---|---|
| UCB | Teknisk/Vetenskaplig/F&U Direktör | 2024-07-01 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Direktör/Styrelseledamot | 2020-09-01 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Företagsledare/Principal | 2017-01-01 |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | 2006-01-01 |
| ░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 15 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Duke University Medical Center
 Duke University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University School of Medicine
 Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
Priothera Ltd.
 Priothera Ltd. Pharmaceuticals: MajorHealth Technology Develops hematological malignancies cells | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
